Envoy Medical COCHW
NASDAQ COCHW
$0.03 +0.00 (+1.58%)
As of: Nov 6, 2026 · 3:55 PM EST

Envoy Medical (COCHW) Raw Materials (2022 - 2026)

Updated

Envoy Medical (COCHW) recorded Raw Materials of $1.32 million in Q2 2026, down 6.3% from $1.41 million a year earlier but up 5.9% from the prior quarter.

Analysis

Envoy Medical (COCHW) Raw Materials (2022 - 2026) Analysis & Trends

At the end of FY2025, Envoy Medical reported Raw Materials of $1.26 million, down 8.9% from FY2024.

  • Annual Raw Materials has a three-year compound annual growth rate of 7.7% (FY2022 to FY2025).
  • Across earlier years, Raw Materials came in at $1.39 million in FY2024 (+19.3%), $1.16 million in FY2023 (+15.0%) and $1.01 million in FY2022.
  • Quarterly Raw Materials has ranged from $1.01 million in Q4 2022 to $1.44 million in Q1 2025 over the past five years.
  • On a year-over-year basis, Raw Materials has declined for three consecutive quarters, with growth averaging 2.4% over the last eight quarters.
  • Peak year-over-year performance for Raw Materials in the last five years was growth of 19.3% in Q4 2024, against a decline of 13.6% in Q1 2026 at the low end.
  • Per Business Quant, the preceding three quarters came in at $1.24 million (Q1 2026), $1.26 million (Q4 2025) and $1.37 million (Q3 2025).
Peer Set

Peer Comparison

Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.32 Mn
Mar 31, 2026 1.24 Mn
Dec 31, 2025 1.26 Mn
Sep 30, 2025 1.37 Mn
Jun 30, 2025 1.41 Mn
Mar 31, 2025 1.44 Mn
Dec 31, 2024 1.39 Mn
Sep 30, 2024 1.36 Mn
Jun 30, 2024 1.39 Mn
Mar 31, 2024 1.24 Mn
Dec 31, 2023 1.16 Mn
Sep 30, 2023 1.23 Mn
Dec 31, 2022 1.01 Mn
API Access

Envoy Medical Raw Materials API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=raw-materials&ticker=COCHW&period=max&api_key=YOUR_API_KEY